Scarica l'app Stockscreener
96.70
5.68%
-5.82
Pre-mercato:
96.33
-0.37
-0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Incyte Corp Borsa (INCY) Ultime notizie
Incyte stock holds Market Perform rating at Citizens on CALR therapy lead - Investing.com
Is Incyte (INCY) Quietly Reframing Its R&D Story With Breakthrough Status And Legal Firepower? - Yahoo Finance
Incyte (INCY) Reports Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte’s experimental drug shows strong response in blood disorder By Investing.com - Investing.com Canada
Incyte’s experimental drug shows strong response in blood disorder - Investing.com
Incyte presents data showing 90% response rate for blood cancer drug - StreetInsider
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia - Business Wire
Institution Moves: Why Incyte Corporation ICY stock stays undervaluedWatch List & Short-Term Trading Alerts - BỘ NỘI VỤ
Incyte (NASDAQ:INCY) Trading Down 6.6%Should You Sell? - MarketBeat
Incyte (INCY) Maintained as Equal-Weight by Morgan Stanley with Raised Price Target | INCY Stock News - GuruFocus
Incyte gains FDA Breakthrough designation for its candidate against essential thrombocythemia - marketscreener.com
INCY: Wells Fargo Raises Price Target to $116 | INCY Stock News - GuruFocus
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status - Yahoo Finance
Incyte (INCY) Stock Receives Upgraded Rating and Price Target from Mizuho | INCY Stock News - GuruFocus
What's Going On With Incyte Stock Monday?Incyte (NASDAQ:INCY) - Benzinga
Leerink Partners Adjusts Incyte Price Target to $128 From $103, Maintains Outperform Rating - marketscreener.com
Incyte stock price target raised to $128 by Leerink on mCALR data - Investing.com
Incyte Corporation $INCY Shares Purchased by American Century Companies Inc. - MarketBeat
Incyte Says Rare Blood Cancer Therapy Receives FDA Breakthrough Designation - marketscreener.com
Incyte Names Veteran Biopharma Attorney as New General Counsel - MyChesCo
Wells Fargo Adjusts Price Target on Incyte to $116 From $97, Maintains Overweight Rating - marketscreener.com
Mizuho upgrades Incyte stock rating to Outperform on promising ASH data - Investing.com
Incyte stock price target raised by BofA to $118 on promising blood disorder data - Investing.com
Mizuho Upgrades Incyte to Outperform From Neutral, Adjusts Price Target to $121 From $90 - marketscreener.com
First Trust Advisors LP Sells 12,101 Shares of Incyte Corporation $INCY - MarketBeat
Transcript : Incyte CorporationSpecial Call - marketscreener.com
Incyte (INCY) Secures FDA Breakthrough Therapy Designation for I - GuruFocus
Incyte (INCY) Reveals Promising Phase 1 Results for INCA033989 i - GuruFocus
Incyte (INCY) Receives FDA Breakthrough Therapy Designation for INCA033989 - GuruFocus
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025 - Yahoo Finance
Incyte: Buy At This Inflection Point (NASDAQ:INCY) - Seeking Alpha
Lido Advisors LLC Buys Shares of 13,529 Incyte Corporation $INCY - MarketBeat
Marshall Wace LLP Takes Position in Incyte Corporation $INCY - MarketBeat
Incyte Corporation $INCY Shares Bought by Fisher Asset Management LLC - MarketBeat
Dodge & Cox Sells 269,147 Shares of Incyte Corporation $INCY - MarketBeat
Insider Selling: Incyte (NASDAQ:INCY) EVP Sells 20,105 Shares of Stock - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 3, 2025 - BioSpace
Incyte Corporation (NASDAQ:INCY) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
VP Stein Sells 22,664 ($2.3M) Of Incyte Corp [INCY] - TradingView
Global Vitiligo Foundation Applauds Partnership Between Incyte and Winnie Harlow to Elevate Awareness and Understanding of Vitiligo - Yahoo Finance
Myeloproliferative Disorder Treatment Market Size Report 2032 - openPR.com
Mackenzie Financial Corp Has $24.67 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Korea Investment CORP Decreases Stake in Incyte Corporation $INCY - MarketBeat
Incyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding - Business Wire
Incyte Appoints Richard Hoffman as Executive Vice President and General Counsel - BioSpace
Hsbc Holdings PLC Cuts Position in Incyte Corporation $INCY - MarketBeat
Incyte (INCY): Evaluating Valuation Following Recent Share Price Momentum - Yahoo Finance
Incyte Corp. stock underperforms Monday when compared to competitors - MarketWatch
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MSN
Incyte appoints Richard Hoffman as executive VP and general counsel By Investing.com - Investing.com Nigeria
Incyte appoints Richard Hoffman as executive VP and general counsel - Investing.com
CACS Drug Market Accelerates at 3.9% CAGR to 2033, Reaching USD - openPR.com
Incyte Corporation $INCY Shares Purchased by Russell Investments Group Ltd. - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Decreases Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Vinva Investment Management Ltd Buys 92,379 Shares of Incyte Corporation $INCY - MarketBeat
Incyte Corporation $INCY Shares Sold by Franklin Resources Inc. - MarketBeat
Incyte (INCY) Up 17.2% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Incyte Corporation $INCY Shares Purchased by North Star Asset Management Inc. - MarketBeat
Incyte: This Profitable Biotech Trades Like A Melting Iceberg (NASDAQ:INCY) - Seeking Alpha
Swiss National Bank Has $33.91 Million Holdings in Incyte Corporation $INCY - MarketBeat
Incyte: Riding Jakafi, Bracing For Generic Headwinds (NASDAQ:INCY) - Seeking Alpha
Incyte’s principal accounting officer Tray Thomas sells $79k in stock - Investing.com
Incyte Corp's Principal Accounting Officer Sells Shares - TradingView
Officer Tray Sells 769 ($79K) Of Incyte Corp [INCY] - TradingView
Incyte receives the first letter confirming compliance following the FDA’s Untitled Letter spree - Medical Marketing and Media
Opzelura From Incyte Corp. - Pharmacy Times
DCF Advisers LLC Has $2.83 Million Stock Holdings in Incyte Corporation $INCY - MarketBeat
Incyte Corp. Stock Climbs 4.1%, Outperforms Peers - 富途牛牛
Integra LifeSciences, Evolent Health, Incyte, iRhythm, and Clover Health Stocks Trade Up, What You Need To Know - Yahoo Finance
Incyte (INCY): Barclays Raises Price Target to $115, Maintains O - GuruFocus
0.63%
2.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):